PONESIMOD for Relapsing-remitting multiple sclerosis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 16 adverse event reports in the FDA FAERS database where PONESIMOD was used for Relapsing-remitting multiple sclerosis.
Most Reported Side Effects for PONESIMOD
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Product dose omission issue | 41 | 13.3% | 0 | 1 |
| Fatigue | 23 | 7.4% | 0 | 1 |
| Dizziness | 16 | 5.2% | 0 | 0 |
| Dyspnoea | 16 | 5.2% | 0 | 1 |
| Headache | 11 | 3.6% | 0 | 0 |
| Covid-19 | 10 | 3.2% | 0 | 4 |
| Drug ineffective | 9 | 2.9% | 0 | 0 |
| Hypoaesthesia | 9 | 2.9% | 0 | 1 |
| Multiple sclerosis relapse | 9 | 2.9% | 0 | 3 |
| Nausea | 9 | 2.9% | 0 | 1 |
| Pain | 8 | 2.6% | 0 | 1 |
| Somnolence | 8 | 2.6% | 0 | 1 |
| Therapy interrupted | 8 | 2.6% | 0 | 2 |
| Hypersensitivity | 7 | 2.3% | 0 | 0 |
| Multiple sclerosis | 7 | 2.3% | 0 | 3 |
Other Indications for PONESIMOD
Multiple sclerosis (137)
Product used for unknown indication (132)
Relapsing multiple sclerosis (12)
Other Drugs Used for Relapsing-remitting multiple sclerosis
OCRELIZUMAB (15,658)
FINGOLIMOD (8,814)
OFATUMUMAB (3,864)
DIMETHYL (3,638)
NATALIZUMAB (2,749)
INTERFERON BETA-1A (2,058)
GLATIRAMER (1,965)
ALEMTUZUMAB (1,604)
TERIFLUNOMIDE (1,320)
RITUXIMAB (956)